Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV ketamine for suicidal ideation in major depressive disorder
IRCT2015030921397N1Phase 2Completed
- Sponsor
- Hormozgan University of Medical Sciences
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ketamine in major depressive disorder (MDD) and suicidal ideation (2 arms), sponsored by Hormozgan University of Medical Sciences. Primary endpoint: Change in suicidal ideation. Started Apr 2015; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)suicidal ideation
Beyond the preview
Go deeper on IRCT2015030921397N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2015030921397N1.